Alembic Pharma Receives USFDA Approval for Generic Ear Infection Medication
Alembic Pharmaceuticals has received final approval from the US Food and Drug Administration for its generic Ciprofloxacin and Dexamethasone Otic Suspension USP, used to treat ear infections in patients aged six months and older. The drug is therapeutically equivalent to Sandoz Inc's Ciprodex Otic Suspension and targets conditions like Acute Otitis Media and Acute Otitis Externa. The product's market size is estimated at USD 110 million through June 2026. This approval brings Alembic's total USFDA ANDA approvals to 246.
First-hand measurement across 2 sources
We measured how 2 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is neutral (58/100). Lens Score 38/100.
Outlets measured: businessstandard, news18. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
Sentiment was consistent across outlets (55–62/100), indicating broadly factual reporting rather than editorialising.
Coverage timeline
news18 broke this story on 19 Oct, 10:00 am. Other outlets followed.
- 1